FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316447403> ?p ?o ?g. }

• W2316447403 endingPage "5368" @default.
• W2316447403 startingPage "5368" @default.
• W2316447403 abstract "Abstract Anti-CTLA-4 therapy (Ipilimumab, Yervoy™) was recently FDA-approved for the treatment of metastatic melanoma based on improved median overall survival observed in Phase III clinical trials. Since anti-CTLA-4 targets a T cell specific molecule, as opposed to a tumor specific molecule, it is being investigated as treatment for multiple malignancies, including prostate cancer. Given that anti-CTLA-4 mediates anti-tumor responses by enhancing T cell responses, it has been postulated that standard agents that enable tumor cell death may allow for priming of a T cell immune response that can be augmented by combination with CTLA-4 blockade. Therefore, we hypothesized that adding ipilimumab to standard androgen ablation (AA) therapy in men with metastatic prostate cancer (mPC) would improve immune and clinical responses. We designed a clinical trial whereby men with castrate-sensitive mPC, ECOG performance status ≤ 2 and normal organ and marrow function are registered ≤1 month of initiation of an LHRH agonist or antagonist (LHRHa). Men with autoimmune diseases, known brain metastases, small cell carcinoma morphology, known HIV, Hepatitis B or C infection, untreated symptomatic spinal cord compressions or chronic immunosuppressive therapies are excluded. Starting on day 29, patients receive 4 monthly doses of 10mg/kg ipilimumab. The primary endpoint of the trial is to estimate the rate of PSA ≤ 0.2ng/mL at 7 months, shown to be a powerful predictor of survival (Hussain et al. J Clin Oncol. 2006; 24:3984). Secondary endpoints include: immune responses, time to testosterone recovery (&gt;50ng/mL), time to disease progression off AA, overall survival and safety of the combination.Accrual is ongoing. Data from 8 patients accrued to date show a significant increase in the frequency of T cells expressing the inducible costimulator (ICOS), as we have previously shown with ipilimumab monotherapy (Liakou et al. Proc Natl Acad Sci U S A. 2008;105:14987; Carthon et al. Clin Cancer Res. 2010;16:2861), and significant increases in memory T cell markers. ICOS+ T cells play an important role in anti-tumor responses mediated by anti-CTLA-4 therapy (Fu et al. Cancer Res. 2011;71:5445). Significant changes in dendritic, natural killer and macrophage cell populations have not been observed. To date, one patient developed an asymptomatic grade 3 transaminitis after 2 doses of ipilimumab that resolved with high dose steroids. Assessment of immune responses induced by the combination of ipilimumab and AA, and evaluation of clinical endpoints are ongoing. Updated data will be presented. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5368. doi:1538-7445.AM2012-5368" @default.
• W2316447403 created "2016-06-24" @default.
• W2316447403 creator A5021183845 @default.
• W2316447403 creator A5042976999 @default.
• W2316447403 creator A5046135731 @default.
• W2316447403 creator A5048915309 @default.
• W2316447403 creator A5052779340 @default.
• W2316447403 creator A5057758356 @default.
• W2316447403 creator A5058115259 @default.
• W2316447403 creator A5060656191 @default.
• W2316447403 creator A5062740919 @default.
• W2316447403 creator A5071033599 @default.
• W2316447403 date "2012-04-01" @default.
• W2316447403 modified "2023-09-25" @default.
• W2316447403 title "Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma" @default.
• W2316447403 doi "https://doi.org/10.1158/1538-7445.am2012-5368" @default.
• W2316447403 hasPublicationYear "2012" @default.
• W2316447403 type Work @default.
• W2316447403 sameAs 2316447403 @default.
• W2316447403 citedByCount "1" @default.
• W2316447403 countsByYear W23164474032013 @default.
• W2316447403 crossrefType "journal-article" @default.
• W2316447403 hasAuthorship W2316447403A5021183845 @default.
• W2316447403 hasAuthorship W2316447403A5042976999 @default.
• W2316447403 hasAuthorship W2316447403A5046135731 @default.
• W2316447403 hasAuthorship W2316447403A5048915309 @default.
• W2316447403 hasAuthorship W2316447403A5052779340 @default.
• W2316447403 hasAuthorship W2316447403A5057758356 @default.
• W2316447403 hasAuthorship W2316447403A5058115259 @default.
• W2316447403 hasAuthorship W2316447403A5060656191 @default.
• W2316447403 hasAuthorship W2316447403A5062740919 @default.
• W2316447403 hasAuthorship W2316447403A5071033599 @default.
• W2316447403 hasConcept C121608353 @default.
• W2316447403 hasConcept C126322002 @default.
• W2316447403 hasConcept C143998085 @default.
• W2316447403 hasConcept C203092338 @default.
• W2316447403 hasConcept C2777701055 @default.
• W2316447403 hasConcept C2777899217 @default.
• W2316447403 hasConcept C2780192828 @default.
• W2316447403 hasConcept C2781433595 @default.
• W2316447403 hasConcept C535046627 @default.
• W2316447403 hasConcept C71924100 @default.
• W2316447403 hasConceptScore W2316447403C121608353 @default.
• W2316447403 hasConceptScore W2316447403C126322002 @default.
• W2316447403 hasConceptScore W2316447403C143998085 @default.
• W2316447403 hasConceptScore W2316447403C203092338 @default.
• W2316447403 hasConceptScore W2316447403C2777701055 @default.
• W2316447403 hasConceptScore W2316447403C2777899217 @default.
• W2316447403 hasConceptScore W2316447403C2780192828 @default.
• W2316447403 hasConceptScore W2316447403C2781433595 @default.
• W2316447403 hasConceptScore W2316447403C535046627 @default.
• W2316447403 hasConceptScore W2316447403C71924100 @default.
• W2316447403 hasIssue "8_Supplement" @default.
• W2316447403 hasLocation W23164474031 @default.
• W2316447403 hasOpenAccess W2316447403 @default.
• W2316447403 hasPrimaryLocation W23164474031 @default.
• W2316447403 hasRelatedWork W1996941066 @default.
• W2316447403 hasRelatedWork W2045770655 @default.
• W2316447403 hasRelatedWork W2083087373 @default.
• W2316447403 hasRelatedWork W2126688981 @default.
• W2316447403 hasRelatedWork W2164192707 @default.
• W2316447403 hasRelatedWork W2241327951 @default.
• W2316447403 hasRelatedWork W2244450389 @default.
• W2316447403 hasRelatedWork W2751779650 @default.
• W2316447403 hasRelatedWork W2913942481 @default.
• W2316447403 hasRelatedWork W2936646021 @default.
• W2316447403 hasVolume "72" @default.
• W2316447403 isParatext "false" @default.
• W2316447403 isRetracted "false" @default.
• W2316447403 magId "2316447403" @default.
• W2316447403 workType "article" @default.